Top entities: Insulet Corporation, Robbins Geller Rudman & Dowd LLP, Ken Dolitsky, Michael Albert.

What category does this event fall under?

Regulatory — classified as securities litigation.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Insulet Corporation disclosed manufacturing issue · Robbins Geller Rudman & Dowd LLP filed securities class action Insulet Corporation

Is this event still developing?

This is an active story, last updated Aug 20, 2026. Coverage continues to evolve.

Regulatory securities litigation

Insulet securities class action lead plaintiff deadline

Q: When did this event occur?

First reported Aug 18, 2026; last updated Aug 20, 2026.

Q: What is the market impact?

General. The class action lawsuit and associated manufacturing corrections have negatively impacted Insulet's stock price and investor confidence.

Analysis based on 6 articles · First reported Aug 18, 2026 · Last updated Aug 20, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit and associated manufacturing corrections have negatively impacted Insulet's stock price and investor confidence. The legal proceedings and potential liability could further pressure the company's valuation and reputation in the medical device market.

Medical Devices Healthcare

Event Summary

Robbins Geller Rudman & Dowd LLP LLP announced that investors who purchased Insulet Corporation securities between February 21, 2025 and May 26, 2026 have until August 31, 2026 to seek appointment as lead plaintiff in a securities class action lawsuit. The lawsuit, Hu v. Insulet Corporation, No. 26-cv-013062 (D. Mass.), alleges that Insulet and certain current and former executives violated the Securities Exchange Act of 1934 by making false or misleading statements and failing to disclose defective manufacturing controls and procedures. These issues allegedly led to voluntary Medical Device Corrections in March and May 2026 for Omnipod products, causing stock price declines of nearly 7% and more than 5%, respectively. The lead plaintiff process is governed by the Private Securities Litigation Reform Act of 1995.

Key Actions

100 Insulet Corporation disclosed manufacturing issue

100 Robbins Geller Rudman & Dowd LLP filed securities class action Insulet Corporation

Entities Involved

stock

Insulet Corporation

Insulet is the defendant in the securities class action, facing allegations of securities fraud related to manufacturing defects and product corrections. The lawsuit and stock declines have negatively affected its market sentiment.

Importance 100.0 Sentiment -40.0

priv

Robbins Geller Rudman & Dowd LLP

Robbins Geller is the law firm representing the class in the lawsuit, seeking lead plaintiff. The firm benefits from the case's visibility and potential recovery, enhancing its reputation.

Importance 80.0 Sentiment 20.0

per

Ken Dolitsky

Ken Dolitsky is an attorney at Robbins Geller involved in the case, serving as a contact for investors. His role is procedural and does not directly affect market sentiment.

Importance 30.0 Sentiment 0.0

per

Michael Albert

Michael Albert is an attorney at Robbins Geller involved in the case, serving as a contact for investors. His role is procedural and does not directly affect market sentiment.

Importance 30.0 Sentiment 0.0

Relationships

Robbins Geller Rudman & Dowd LLP related ↔ Ken Dolitsky

Robbins Geller Rudman & Dowd LLP related ↔ Michael Albert

Ken Dolitsky principal ↔ Michael Albert Ken Dolitsky is an associate attorney at Robbins Geller Rudman & Dowd LLP, working under Michael Albert, a partner, on v

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard